LOCAL

BG Medicine gives partnership updates, financial results

Staff Writer
MetroWest Daily News

WALTHAM — BG Medicine Inc, the developer of the BGM Galectin-3(R) Test, recently provided an update on business developments and the U.S. market introduction of automated testing for galectin-3 by its partner Abbott and reported financial results for the second quarter of 2015.

Representatives from BG Medicine joined with Abbott personnel to help communicate the utility of galectin-3 testing to laboratory and healthcare professionals who were attending the American Association of Clinical Chemistry Annual Meeting held July 26-29 in Atlanta.

The company reported net loss for the second quarter of 2015 of $2.0 million, a six percent improvement from the $2.2 million net loss reported in the second quarter of 2014.